Literature DB >> 17658755

V-PROLI/NO, a prodrug of the nitric oxide donor, PROLI/NO.

Harinath Chakrapani1, Brett M Showalter, Li Kong, Larry K Keefer, Joseph E Saavedra.   

Abstract

The sensitivity to decomposition of the nitric oxide (NO) donor ion, 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), complicates direct electrophilic substitution to form useful prodrug derivatives. A modified general synthetic approach involving 1-[2-(hydroxymethyl)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate ion (structure A, above) was used to prepare several PROLI/NO prodrugs including the previously inaccessible O2-vinyl derivative, V-PROLI/NO. Metabolism of V-PROLI/NO by liver microsomes enriched in human cytochrome P450 isoforms was demonstrated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17658755     DOI: 10.1021/ol701419a

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  13 in total

1.  The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of Proline.

Authors:  Sam Y Hong; Gregory L Borchert; Anna E Maciag; Rahul S Nandurdikar; Joseph E Saavedra; Larry K Keefer; James M Phang; Harinath Chakrapani
Journal:  ACS Med Chem Lett       Date:  2010-11-11       Impact factor: 4.345

Review 2.  Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways.

Authors:  Robert Y S Cheng; Debashree Basudhar; Lisa A Ridnour; Julie L Heinecke; Aparna H Kesarwala; Sharon Glynn; Christopher H Switzer; Stefan Ambs; Katrina M Miranda; David A Wink
Journal:  Nitric Oxide       Date:  2014-08-19       Impact factor: 4.427

3.  Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.

Authors:  Harinath Chakrapani; Michael M Goodblatt; Vidya Udupi; Swati Malaviya; Paul J Shami; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

4.  Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1.

Authors:  Wei Qu; Lida Cheng; Anna L Dill; Joseph E Saavedra; Sam Y Hong; Larry K Keefer; Michael P Waalkes
Journal:  Chem Biol Interact       Date:  2011-05-20       Impact factor: 5.192

Review 5.  Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy.

Authors:  Jihoon Kim; Bryant C Yung; Won Jong Kim; Xiaoyuan Chen
Journal:  J Control Release       Date:  2016-12-26       Impact factor: 9.776

6.  Structurally Diverse Nitric Oxide-Releasing Poly(propylene Imine) Dendrimers.

Authors:  Yuan Lu; Bin Sun; Chenghong Li; Mark H Schoenfisch
Journal:  Chem Mater       Date:  2011-09-27       Impact factor: 9.811

7.  Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs.

Authors:  Harinath Chakrapani; Anna E Maciag; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  Org Lett       Date:  2008-10-29       Impact factor: 6.005

8.  Glycosylated PROLI/NO derivatives as nitric oxide prodrugs.

Authors:  Rahul S Nandurdikar; Anna E Maciag; Sam Y Hong; Harinath Chakrapani; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  Org Lett       Date:  2010-01-01       Impact factor: 6.005

9.  Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.

Authors:  Daniela Andrei; Anna E Maciag; Harinath Chakrapani; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

10.  Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.

Authors:  Harinath Chakrapani; Thomas C Wilde; Michael L Citro; Michael M Goodblatt; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem       Date:  2007-11-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.